{
  "docId": "019de074-1cfe-7508-8ae3-4ba4db03f42e",
  "docSlug": "98d74dc525a4b13d13a1ee51c3af4583",
  "documentTitle": "Kymera | Results Presentation Deck | 63 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 63,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The slide validates clinical findings against preclinical models.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-1cfe-7508-8ae3-4ba4db03f42e/13",
  "deckHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e",
  "deckJsonHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e.json",
  "deckAnchorHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.1,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Clinical PD in PBMC by MS",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19ab8267-2f07-49ee-b7b8-3a05127b7c9b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "list",
      "text": "Observed STAT3 degradation of 50-80% in PBMCs at Dose Level 1 is consistent with the range predicted for tumor based on preclinical modeling of SUDHL1 xenograft PK-PD data",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b6dce7e-a0a6-428d-980b-efa0b7345f34",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "list",
      "text": "Maximal degradation in DL1 patients is observed between 24-96 hours post infusion in Cycle 1 weeks 1 & 2, with recovery of STAT3 levels between doses, as seen in preclinical models",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d414489d-f50b-470a-b4f2-bc8beeac2dd6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.18
      },
      "kind": "table",
      "text": "Subject ID and Mean Max Degradation table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "168e4c60-9c09-4946-80dd-dfadd542d660",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "STAT3 Degradation in Blood at Dose Level 1 (DL1: 0.05 mpk) Consistent with Prediction from Preclinical Modeling",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef559db5-ad1a-4195-8c59-60568ab85722",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "bb8d115f-c4b0-4247-8fc9-5bb7023f78a7",
      "evidence": "Compares clinical observation to preclinical prediction",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 15,
      "from": 5,
      "beatId": "69f2d34e-b7ab-4885-8215-0582cdf92a83",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitation",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Discussion of current treatment limitations and Kymera's solution",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 13,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "d2ba16ef-fee8-4e4f-a8a2-6322f08cccfe",
      "evidence": "STAT3 degradation in blood at dose level 1",
      "position": 0,
      "objective": "Demonstrate initial proof-of-mechanism for KT-333",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.8,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}